|
Jul 2
|
Oppenheimer Reaffirms Outperform on Revolution Medicines, Cites PDAC and NSCLC Trial Progress
|
|
Jun 30
|
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
|
|
Jun 24
|
Revolution Medicines Signs $2 Billion Funding Deal With Royalty Pharma
|
|
Jun 24
|
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
|
|
Jun 23
|
Sector Update: Health Care Stocks Mixed in Afternoon Trading
|
|
Jun 23
|
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
|
|
Jun 20
|
This Revolution Medicines Insider Increased Their Holding In The Last Year
|
|
Feb 19
|
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025
|